Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients.

Berta E, Harangi M, Zsíros N, Nagy EV, Paragh G, Bodor M.

Pharmazie. 2014 Jun;69(6):420-3.

PMID:
24974574
2.

Drug-drug interactions that interfere with statin metabolism.

Hirota T, Ieiri I.

Expert Opin Drug Metab Toxicol. 2015;11(9):1435-47. doi: 10.1517/17425255.2015.1056149. Epub 2015 Jun 11. Review.

PMID:
26058399
3.

Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin.

Zuccaro P, Mombelli G, Calabresi L, Baldassarre D, Palmi I, Sirtori CR.

Pharmacol Res. 2007 Apr;55(4):310-7. Epub 2007 Jan 14.

PMID:
17289397
4.

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Williams D, Feely J.

Clin Pharmacokinet. 2002;41(5):343-70. Review.

PMID:
12036392
5.

Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study.

Tirkkonen T, Ryynänen A, Vahlberg T, Irjala K, Klaukka T, Huupponen R, Laine K.

Drug Saf. 2008;31(3):231-40.

PMID:
18302447
6.

Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.

da Silva PM.

Am J Cardiovasc Drugs. 2011;11(2):93-107. doi: 10.2165/11591190-000000000-00000. Review.

PMID:
21446776
7.

Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge.

Fung EC, Crook MA.

Cardiovasc Ther. 2012 Oct;30(5):e212-8. doi: 10.1111/j.1755-5922.2011.00267.x. Epub 2011 Apr 1.

PMID:
21884002
8.

Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization.

Shanahan RL, Kerzee JA, Sandhoff BG, Carroll NM, Merenich JA.

Pharmacotherapy. 2005 Mar;25(3):345-51.

PMID:
15843281
9.

Statin induced myotoxicity.

Sathasivam S.

Eur J Intern Med. 2012 Jun;23(4):317-24. doi: 10.1016/j.ejim.2012.01.004. Epub 2012 Feb 4. Review.

PMID:
22560377
10.

Red yeast rice and coenzyme Q10 as safe alternatives to surmount atorvastatin-induced myopathy in hyperlipidemic rats.

Abdelbaset M, Safar MM, Mahmoud SS, Negm SA, Agha AM.

Can J Physiol Pharmacol. 2014 Jun;92(6):481-9. doi: 10.1139/cjpp-2013-0430. Epub 2014 Apr 28.

PMID:
24896301
11.

Statin-associated myopathy.

Hamilton-Craig I.

Med J Aust. 2001 Nov 5;175(9):486-9. Review.

PMID:
11758079
12.

Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD.

Drug Saf. 2010 Mar 1;33(3):171-87. doi: 10.2165/11319380-000000000-00000. Review.

PMID:
20158283
13.
14.

Rosuvastatin: a review of its use in the management of dyslipidemia.

Scott LJ, Curran MP, Figgitt DP.

Am J Cardiovasc Drugs. 2004;4(2):117-38. Review. Erratum in: Am J Cardiovasc Drugs. 2005;5(2):130.

PMID:
15049723
15.

Asymptomatic hypothyroidism and statin-induced myopathy.

Bar SL, Holmes DT, Frohlich J.

Can Fam Physician. 2007 Mar;53(3):428-31. No abstract available.

16.

Statin safety and drug interactions: clinical implications.

Bottorff MB.

Am J Cardiol. 2006 Apr 17;97(8A):27C-31C. Epub 2006 Jan 25. Review.

PMID:
16581325
17.

Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.

Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH.

Biopharm Drug Dispos. 2000 Dec;21(9):353-64.

PMID:
11523064
18.

Fluvastatin as co-medication in heart transplant recipients with elevated creatine-kinase.

Sadoni S, Kaczmarek I, Delgado O, Schmöckel M, Reichart B, Meiser B.

Transplant Proc. 2007 Mar;39(2):558-9.

PMID:
17362781
19.

Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy.

Keating AJ, Campbell KB, Guyton JR.

Ann Pharmacother. 2013 Mar;47(3):398-404. doi: 10.1345/aph.1R509. Epub 2013 Mar 12. Review.

PMID:
23482733
20.

Managing statin-induced muscle toxicity in a lipid clinic.

Blaier O, Lishner M, Elis A.

J Clin Pharm Ther. 2011 Jun;36(3):336-41. doi: 10.1111/j.1365-2710.2011.01254.x. Epub 2011 Mar 18.

PMID:
21414023

Supplemental Content

Support Center